The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy and safety of single-agent sunitinib in treating patients with advanced hepatocelluar carcinoma after sorafenib failure: A prospective, open-label, phase II study.
T. Yau
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
R. C. Leung
No relevant relationships to disclose
H. Wong
No relevant relationships to disclose
J. Chiu
No relevant relationships to disclose
P. Chan
No relevant relationships to disclose
R. Pang
No relevant relationships to disclose
S. T. Fan
No relevant relationships to disclose
R. T. P. Poon
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Research Funding - Pfizer